PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO) today announced the launch of Caphosol Relieves Oral Mucositis (CARE OM™), an educational support program for patients and caregivers. The announcement comes as Cytogen establishes an expanded market presence for CAPHOSOL®, an advanced electrolyte solution indicated in the U.S. as an adjunct to standard oral care in treating oral mucositis (OM) caused by radiation or high dose chemotherapy. CAPHOSOL, a prescription medical device, is also indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause or whether the conditions are temporary or permanent.1 CAPHOSOL is available through U.S. wholesalers nationwide.
